development and commercialization agreement for Iclusig
23/12/2014 12:00
Dec 23 (Reuters) - Otsuka Pharmaceutical Co: * Ariad and Otsuka announce co-development and commercialization agreement for iclusig to treat leukemias in Japan and nine other Asian countries * Otsuka Pharmaceutical Co- agreement provides for Otsuka to market Iclusig in Japan and nine other Asian countries for $77.5 million to Ariad * Otsuka Pharmaceutical Co- Ariad will continue to fund the completion of its ongoing pivotal trial of Iclusig * Otsuka Pharmaceutical Co- Otsuka will file the NDA on behalf of both companies for regulatory approval in 2015 * Source text for Eikon ID:nBwbfsWcfa * Further company coverage [4578.T 4768.T ARIA.O 4578.T 4768.T ARIA.O 4578.T 4768.T ARIA.O 4578.T 4768.T ARIA.O] ((Bengaluru Newsroom; +1 646 223 8780))